Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...

STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors Overall, 262 patients with ER+/HER2– ...

CHICAGO — Levothyroxine (LT4) monotherapy remains the standard treatment for hypothyroidism, although a subset of patients continue to have hypothyroidism despite normal thyroid-stimulating hormone ...

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that ...

In a recent study published in the journal Pharmacological Research, researchers investigated the synergistic efficacy of two glycemic control drugs – dapagliflozin and semaglutide. They carried out ...

Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it means treating a tumor with more than one type of therapy at the same time ...

Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan; hereinafter "Kowa"), today announced that on June 11, it received Breakthrough ...

The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with reassurance, ...

Effects of UCHL1 on tolerogenic DC maturation and promotion of mregDC-Treg crosstalk to nullify anti–PD-L1 therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

A Clinical-Stage Molecule Drives Selective In Vivo Expansion of Tumor-Specific T Cells, Achieving 100% Survival in a High Tumor Burden Ovarian Cancer Model and Promoting Strong Tumor Infiltration in a ...